Posted on

What Sets Pharmaceutical Facility CAPEX? 10 Decisions Made Before Construction

What Sets Pharmaceutical Facility CAPEX

Pharmaceutical facility CAPEX is heavily influenced before construction begins. A large share of the eventual cost is shaped earlier, in a handful of design choices that look small on a meeting agenda and large on a bill of quantities. Dosage form, cleanroom class, containment, air strategy, and utility redundancy can shape a large share of the budget before the first drawing goes to site.

Here is why that matters for cost control. You can negotiate unit rates later, but you cannot negotiate your way out of an oversized clean area. Let’s break it down.

Quick Answer: The 10 Decisions That Set Pharma Facility Cost

  1. Dosage form and product mix
  2. Capacity and batch size
  3. Cleanroom classification and extent
  4. Containment level
  5. HVAC zoning and air strategy
  6. Utility generation and redundancy
  7. Automation level
  8. Equipment specification and sourcing
  9. Materials and finishes
  10. Future expansion strategy

Design maturity sits behind all ten. The sections below cover each decision, then the contract, value engineering, and lifecycle cost.

The 10 Decisions Behind Pharma Facility Cost Drivers

The pharma facility planning cost drivers below are listed in the order most teams meet them. Early choices shape the later ones.

1. Dosage Form and Product Mix

Dosage form sets the room list, air classes, utilities, and validation scope. An oral solid dosage line, a sterile injectable line, and a biologics suite can require different facility configurations, environmental controls, utilities and qualification strategies. Pharma Access groups its project work into biotechnology, sterile manufacturing, oral solid dosage, oral liquid dosage, and API, which shows how different these categories are.

A sterile line usually carries more classified area, more utilities, and more qualification work than an oral solid line. Mixed product plans can add segregation rooms, dedicated equipment, and cleaning studies. Settle the product mix before you size anything else.

2. Capacity and Batch Size

Capacity sets room size, equipment size, and utility demand. Build too small and you pay for an expansion within a few years. Build too large and you tie up capital in idle space and idle plant.

Work from annual volume to batch size, shifts, and campaign pattern. Then balance the line so one machine does not cap the output of all the others. Write the design basis down and keep it under change control.

3. Cleanroom Classification and Extent

Cleanroom Classification and Extent

Classification changes cost because it influences the environmental control strategy. Tighter cleanliness requirements can require greater control of airflow, filtration, room pressure and recovery performance, all of which can raise cost. Supply and exhaust air systems are major cost items in a cleanroom, and the cost range depends on classification, airflow strategy, temperature control, pressurisation, and humidity needs. Temperature and relative humidity requirements can also be major cost drivers in cleanroom design and construction, not only classification.

Two questions save money. Which rooms truly expose products? And how tight do temperature and humidity need to be in each one? Apply classification according to process and contamination-control requirements, not automatically to the whole floor.

4. Containment Level

Containment adds airlocks, pressure cascades, dedicated air systems, and sometimes isolators. The challenge is finding a containment strategy that manages exposure risk at a reasonable lifecycle cost. Product protection and worker protection can require different pressure and airflow strategies.

Containment can also be localised at the machine. Localised containment such as isolators or downflow booths can reduce reliance on room-level containment in some applications, depending on product hazard, exposure risk and process design. Define the applicable exposure or containment requirement for each product before you design rooms, because a late upgrade means rebuilding walls and air systems.

5. HVAC Zoning and Air Strategy

HVAC deserves its own decision because it sets both CAPEX and running cost. Benchmarking studies consistently show cleanroom HVAC as a major share of total facility energy use. It can also represent a significant share of a GMP Annex facility’s utility cost.

Zoning is the lever. Appropriate air-handling zoning and control strategies may allow some areas to operate in reduced-airflow modes where this is justified by process risk and qualification. WHO’s HVAC guidance requires filtration, airflow direction and pressure differentials to be selected according to the product, process and level of protection required. Those decisions affect fan size, filter configuration, and duct sizing. Treat any air change reduction as a validated, risk-based decision, not a drawing-stage guess.

6. Utility Generation and Redundancy

Utility Generation and Redundancy

Utilities include water, steam, chilled water, compressed air, nitrogen, power, and effluent treatment. Plant size follows the load list, and the load list follows the earlier decisions. WHO’s guidance on water for pharmaceutical use covers which water grade suits which application and how to design, install, and operate the systems. Use it to avoid supplying a higher grade than a process needs.

Redundancy is a business decision. Duplicate pumps, standby chillers, and backup power cost money. A stopped water loop or failed cooling plant can cost a batch. List the loads that must stay on, such as classified-room HVAC, water circulation, cold storage, and controls, and protect those first.

7. Automation Level

Automation ranges from manual operation with local controls to integrated facility automation such as BMS/EMS and process or equipment automation such as PLC, SCADA, DCS or batch control. More automation raises CAPEX and validation scope. Less automation raises labour and error risk. Match the level to batch records, data integrity needs, and operator skill. Use a risk-based approach, as in ISPE’s GAMP 5 guidance for computerised systems, and avoid building a data system the site cannot support.

8. Equipment Specification and Sourcing

Equipment is a large share of CAPEX, and the user requirement specification controls it. A well-done front-end package lets the specification reflect real process conditions, such as validated flow rates, confirmed material compatibility, and defined utility connections. Vague specifications invite over-specified quotes or wrong machines.

Check more than price. Compare lead time, spare parts support, documentation quality, factory acceptance testing, and the utility loads each supplier states. A cheaper machine with a larger utility demand can raise plant cost elsewhere.

9. Materials and Finishes

Finishes in classified rooms must clean well and survive disinfectants. Pharma cleanrooms carry a higher cost per square foot because their surfaces, junctions and finishes must support cleanability, durability and contamination control. Wall panels, floors, doors, ceilings, and lighting all follow cleanability rules.

Do not apply cleanroom finishes everywhere. Offices, general stores, and plant rooms can use standard materials. Use the premium finish only where the process or the cleaning regime needs it.

10. Future Expansion

Future Expansion projects

Expansion planning costs little on paper and a lot later. Reserve floor area, plant space, electrical capacity, and pipe routes for phase two. Allow for future capacity in utility routes, tie-in points and switchgear where engineering designs and lifecycle analysis justify it, rather than automatically oversizing active systems. Pharma Access describes a Modular Mobile Facility concept on its website, an off-site delivery approach that can support phased growth or schedule acceleration where it suits the project.

Why Design Maturity Beats Unit Price

Teams often chase lower unit rates when they should chase a clearer design. Early work costs little and shapes the outcome. One ISPE article says concept and front-end design typically account for no more than 5 to 10 percent of total project cost, yet they define the outcome of everything else. A BioPharm International article says the first 5 to 15 percent of effort in scope development affects 75 to 90 percent of final cost.

Construction research points the same way. A Department of Energy guide linked a high level of front end planning to roughly 20 percent cost savings and 39 percent schedule savings. That is a cross-industry average, not a pharma promise. Estimate quality also improves with design maturity. ISPE’s project matrix places concept estimates at about plus or minus 30 percent and front-end design estimates at about plus or minus 10 percent.

Late change makes it worse. One study found design-error rework could add around 16 percent to original contract value in construction projects. Pharma construction cost rises fastest when drawings change after equipment is ordered and pipes are installed.

Pharma EPC Project Cost: Contract Choice Matters

The contract model spreads risk, and design maturity decides whether the model works. A fixed price EPC contract is a turnkey model where one contractor handles design, procurement, construction, and commissioning, and typically takes substantial cost and schedule risk under the agreed contract terms. Pharma EPC project cost may look certain on day one, but the price assumes a stable scope. One advisory firm lists design maturity that is fit for purpose and schedule among its tips for using lump sum EPC contracts.

The alternative has trade-offs too. Under cost reimbursable contracts, costs are not capped, so the final price varies and the owner needs strong cost management and oversight. Choose the model after you measure design maturity. A well-defined scope suits a fixed price. An evolving scope may suit a reimbursable or target-cost structure with appropriate incentives and risk allocation.

Pharmaceutical Facility Value Engineering: Where It Helps and Where It Backfires

Value engineering is not a cost cut. One public definition describes it as defining the required function and creating alternatives to provide that function at the lowest life-cycle cost. Pharmaceutical facility value engineering works when it removes cost that serves no function. It fails when it removes function.

Where it helps

  • Trimming classified area to where the process and contamination-control requirements justify it
  • Using standard finishes in non-GMP areas
  • Standardising equipment and spare parts across lines
  • Localising containment at the machine instead of building a larger suite
  • Combining utility generation where loads and risks allow
  • Reducing air change rates through a validated, risk-based study

Where it becomes false economy

  • Cutting redundancy on loads that must stay running
  • Downgrading HVAC controls or monitoring
  • Choosing finishes that fail under routine cleaning
  • Shrinking maintenance access or qualification space
  • Deleting spare plant capacity that expansion will need

Regulated sites carry extra risk. One commissioning firm warns that value engineering in life sciences can create hidden commissioning, validation, and compliance costs, because the systems on the table are rarely cosmetic. The same source says catching a problem at design costs almost nothing, while catching it after occupancy can mean a production hold, a deviation, or a regulatory finding. Record each accepted change and the reason, and ask quality and validation staff to review it.

Lifecycle Cost Pharmaceutical Facility: Look Past Handover

CAPEX is only the first bill. A lifecycle cost pharmaceutical facility view adds energy, maintenance, cleaning, requalification, and spare parts. HVAC can be a major running cost, as shown above. Fan power can represent a substantial share of cleanroom air-handling utility cost.

That changes some choices. A larger duct or a better fan can cost more at the start but lower energy use over its operating life. A cheap system with high pressure drop does the opposite. Compare options over a stated period, and include energy and maintenance, not purchase price alone.

How to Control Cost in a Pharma Turnkey Project

Pharmaceutical project cost control works best as a short sequence:

  1. Write the basis of design. Record products, volumes, classes, containment bands, and expansion plans.
  2. Challenge the room list. Remove classified areas that the process does not need.
  3. Set a cost range, then narrow it. Use wide ranges early and tighter ones as design matures.
  4. Freeze in stages. Lock process data and layout before major orders.
  5. Run value engineering with quality and validation staff. Document every accepted change.
  6. Control change. Require an impact check on cost, schedule, and qualification for every request.
  7. Compare lifecycle cost. Add energy and maintenance to every major option.

Common Mistakes to Avoid

  • Pricing the building before the product mix is settled
  • Classifying every room to the highest level “to be safe”
  • Treating containment as an afterthought
  • Cutting redundancy without a risk review
  • Buying equipment before utility loads are confirmed
  • Reviewing value engineering ideas without quality input

Next Steps

Start with the ten decisions. Write down your current answer to each, mark the weak ones, and close those before detailed design starts. Pharmaceutical products project cost control is easier when the weak spots show up on paper first. Pharma Access shares more facility-planning topics on its blog at the website.

Frequently Asked Questions

What are the biggest cost items in a pharmaceutical facility?

Cleanroom HVAC, process equipment, utilities, and finishes usually lead. Air systems rise with classification, temperature, and humidity needs. Dosage form and containment level decide how much classified area and special equipment the building needs.

How does cleanroom classification affect CAPEX?

Tighter cleanroom requirements can increase the level of control needed for airflow, filtration, pressure, recovery performance and environmental conditions. The exact air-change rate, filtration strategy and airflow pattern should be based on the process, contamination-control strategy and qualification requirements rather than classification alone. Limiting high classification to rooms and operations where it is technically justified is one of the strongest ways to hold CAPEX down.

Is value engineering safe in a GMP facility?

It can be, if quality and validation staff review each change and the team records the reason. Cutting redundancy, controls, or cleanable finishes often adds commissioning, validation, and operating cost later.

Why does design maturity matter for cost control?

Early design choices shape most of the final cost, and late changes trigger rework. Studies cited by ISPE, BioPharm International, and the U.S. Department of Energy tie better front-end work to lower cost and shorter schedules.

Should I choose a lump sum or reimbursable for a pharma EPC project?

It depends on design maturity. A well-defined scope generally suits a fixed price. An evolving scope may suit reimbursable or target-cost terms, depending on the project’s risk allocation. Reimbursable contracts leave more cost risk with the owner and need strong oversight.

Posted on

UAE Pharmaceutical Manufacturing Requirements: EDE, GMP, and Facility Readiness Explained

UAE Pharmaceutical Manufacturing Facility

If you are considering setting up a pharmaceutical factory in the UAE, the regulatory framework has recently undergone a significant change. A number of pharmaceutical licensing and GMP oversight functions have transitioned from the Ministry of Health and Prevention (MOHAP) to the Emirates Drug Establishment (EDE). If your compliance plan is still written on the old structure, now is the time to update it.

This guide provides a practical overview of the UAE pharmaceutical manufacturing requirements. It explains who regulates what, what a factory needs to get licensed, and what GMP looks like on the ground.

Meet the Emirates Drug Establishment (EDE)

The Emirates Drug Establishment (EDE), the UAE’s independent federal authority for pharmaceuticals and medical devices, was established in September 2023 under Federal Decree-Law No. 28 of 2023. Its scope covers all medical and pharmaceutical products manufactured in the country, including medical devices and other medical-product categories within its statutory mandate.

A further regulatory shift followed. Federal Decree-Law No. 38 of 2024 entered into force on 2 January 2025, replacing the older Federal Law No. 8 of 2019. As part of the implementation of this transition, MOHAP announced the full transfer of 44 core services to EDE, together with the partial transfer of 13 additional services, including pharmaceutical-facility licensing functions. EDE now administers medical-product factory licensing and GMP certification through its regulatory services.

MOHAP still exists. It continues to retain specific pharmaceutical-sector responsibilities, including licensing medical professionals and pharmacists supporting EDE-licensed establishments, as well as certain controlled-medicine functions. Abu Dhabi also maintains its own Approved Drug List and processes for certain non-registered medicines within the local healthcare system through the Department of Health (DOH); these are distinct from the federal EDE manufacturing-licensing process. So a manufacturer operating across emirates may need to coordinate with federal and relevant local authorities depending on the project and market pathway, rather than dealing with only one authority.UAE Legislation

Why This Matters for Facility Planning

Why This Matters for Facility Planning

This is an important distinction during regulatory and facility planning. While pharmaceutical facility licensing and EU GMP approval in the UAE are processed at the federal level, specific healthcare-market requirements in Abu Dhabi are managed by the DOH. If your plant is in Dubai, you work with the EDE for manufacturing approval. Separate emirate-level requirements, such as industrial, environmental, municipality and Civil Defence approvals, may also form part of the overall project pathway. If your products are intended for specific Abu Dhabi healthcare channels, applicable DOH requirements become an additional local-market consideration.

This is not a sequence in which one approval leads automatically to the next. These are different regulatory and project-approval tracks and early planning saves a lot of back and forth later.

Core UAE Pharmaceutical Manufacturing Requirements

Core UAE Pharmaceutical Manufacturing Requirements

Whether you are setting up a new plant or expanding an existing one, the basic route to a pharmaceutical manufacturing licence in the UAE goes through a few stages.

Stage 1: Initial Approval and Site Planning

The applicant will provide company and site information for review before construction. This includes the ownership structure, corporate documents, project feasibility information and the documentation required for initial regulatory review. Current EDE requirements place the proposed pharmaceutical dosage forms and production lines under the subsequent construction and preparation stage rather than the initial-approval documentation.

Stage 2: Construction and Preparation

After the initial approval is obtained, the facility begins to build out the physical plant. Detailed engineering drawings, approval related to estimated water and electricity consumption where required, a list of the pharmaceutical forms and proposed production lines, the equipment and devices for each production, packaging, and sterilisation line where applicable, and an explanation of what the quality control laboratory needs to operate are required at this stage. Then, once these documents have been submitted and the relevant requirements fulfilled, the facility will be eligible to submit a GMP inspection request through EDE.

Stage 3: Final Licensing and GMP Certificate

The facility appoints appropriately qualified and licensed personnel to fill key positions, including production manager, quality assurance manager, and quality control manager, before final inspection. These positions require valid professional licences, with pharmacist and medical-professional licensing for the relevant roles handled through MOHAP. Personnel requirements for facilities limited to medical devices may differ from those applicable to pharmaceutical manufacturing facilities. After the inspection has been completed and the documents verified, the final licence and GMP certificate are issued after the facility has addressed the applicable requirements and inspection observations.

According to the current EDE service information, the government fee for final licensing of a pharmaceutical or medical device manufacturing facility is AED 50,000. EDE also currently lists an AED 100 application fee, AED 2,000 for engineering-plan approval and AED 3,000 for each final inspection. The separate GMP compliance certificate is currently listed at AED 2,000 per production line annually.

Stage 4: Renewal and Ongoing Compliance

In the UAE, a pharmaceutical factory licence must be renewed annually, and renewal is based on continued compliance with good manufacturing practices, confirmed through inspection. EDE states that requests to renew EDE-issued GMP certificates can be submitted approximately two months before expiry. Factory-licence renewal and GMP inspection therefore should not be treated as completely separate activities, because continued GMP compliance is part of the renewal requirements. This is not something to leave at the last minute, as failing to renew on time can have legal consequences.

What GMP Actually Covers Inside the Plant

UAE GMP certification requirements are not just paperwork exercises. Inspectors observe the real operation of the facility. 

There are a few areas that crop up again and again:

  • Facility layout and cleanliness. The building needs to be designed to allow materials and staff to pass through in a logical order, with appropriate segregation and controls to minimise contamination and cross-contamination risks.
  • Facilities and utilities. The equipment used for production and packaging must meet the set standards. Utilities that directly or indirectly affect product quality, including pharmaceutical water, HVAC and process gases where applicable, require appropriate qualification, monitoring and maintenance.
  • Documentation and quality system. Standard operating procedures, batch records, and deviation logs must exist and must match what is really happening on the floor.
  • Personnel trained. Production staff need role-specific training, and that training needs a paper trail.
  • Testing of products. Raw materials, in-process samples where applicable, and finished products should be tested against defined specifications.

This is nothing unique to the UAE. It is closely aligned with established international GMP principles, while manufacturers must also meet the specific UAE regulatory requirements applicable to their facility, products and processes.

How UAE Requirements Connect to GCC Drug Registration

It is rare that the UAE is the only market a manufacturer has in mind when building a plant in the UAE. A lot of companies are looking for broader GCC drug registration, so they use the UAE as a base to get to Saudi Arabia, Qatar, Oman, Bahrain, and Kuwait as well.

The UAE fits into this regional picture in two ways. First of all, a GMP certificate from the EDE can form part of the regulatory evidence supporting applications involving a UAE manufacturing site, but it does not by itself provide automatic regulatory approval in other GCC markets. The Gulf Health Council also operates a central drug-registration framework intended to harmonise registration of pharmaceutical companies and medicines across GCC member states. Secondly, UAE-based manufacturing can be a strategic entry point, thanks to the country’s logistics infrastructure and its position as a gateway to the wider Gulf market.

That said, Gulf Health Council central-registration requirements and country-specific regulatory requirements may still apply depending on the intended product and market pathway, so a UAE GMP certificate doesn’t automatically clear every hurdle elsewhere in the region.Emirates Drug Establishment

Common Mistakes Manufacturers Make

A handful of patterns are common enough to be worth mentioning:

  1. Treating EDE and DOH requirements as one combined approval process. They cover different regulatory responsibilities, and confusing their roles can create unnecessary delays.
  2. Finalising engineering drawings before confirming the intended dosage forms, production lines and manufacturing scope. Once construction drawings are locked in, changing the product mix can mean expensive rework.
  3. Under-scoping the quality control laboratory. EDE requires manufacturers to define the equipment needed for laboratory testing of raw materials, in-process materials and finished products. An inadequately planned QC laboratory can create gaps in inspection readiness.
  4. Waiting too long to renew. EDE allows requests to renew its GMP certificates approximately two months before expiry, while continued GMP compliance remains part of the factory-licence renewal process.
  5. Assuming old MOHAP processes are still applicable across the board. EDE now administers key manufacturing licensing and GMP services, so older guidance should be checked against the current EDE process before it is relied upon.

Getting the Facility Design Right the First Time

Much of the above delay can be traced back to decisions made before one wall is built. Getting the layout of the building, the cleanroom classification,where required by the product and process,  and the design of the utilities right at the drawing-board stage helps avoid the costly redesign work that rears up later when inspectors point out gaps. This is where Pharma Access comes in, working with pharmaceutical manufacturers at this very stage, designing facilities to meet GMP expectations from day one, rather than retrofitting compliance into a finished building.

Pharma Access also provides support for commissioning, qualification, and validation (CQV) work for projects that need assistance in linking engineering decisions to documented GMP requirements and inspection readiness. This is the stage at which a finished facility is tested against the approved requirements and intended operating conditions that support its qualified state and readiness for GMP manufacturing.

A Few Final Thoughts

The Emirates Drug Establishment is now the principal federal authority administering pharmaceutical manufacturing licensing and GMP certification in the UAE, MOHAP continues to perform specific responsibilities including professional licensing and certain controlled-medicine functions, and DOH Abu Dhabi has its own healthcare-market responsibilities within Abu Dhabi. 

To obtain a licence for a plant, the process includes initial approval, construction and preparation, GMP inspection and qualified-personnel readiness, final licensing with a GMP certificate, and then annual renewal. Build the facility with GMP expectations integrated into the design from day one, and the risk of late-stage redesign can be reduced while inspection readiness is strengthened.Department of Health

Frequently Asked Questions

What is the Emirates Drug Establishment (EDE), and how is it different from MOHAP? 

The EDE is the UAE’s federal authority for the regulation of pharmaceuticals and medical devices, established in 2023. As part of the regulatory transition implemented during 2025, MOHAP transferred 44 core services fully and 13 services partially to EDE. EDE now administers key services involving medical-product manufacturing facilities and GMP compliance, while MOHAP retains responsibilities including professional licensing and certain controlled-medicine functions.

How much does a pharmaceutical manufacturing licence cost in the UAE? 

According to current EDE service information, the final licensing fee for pharmaceutical or medical device manufacturing facilities is AED 50,000. EDE also currently lists an AED 100 application fee, AED 2,000 engineering-plan approval fee and AED 3,000 per final inspection. The GMP compliance certificate is listed separately at AED 2,000 per production line annually. Fees should always be reconfirmed with EDE before submission because regulatory charges can change.

How often does a UAE GMP certificate need renewal? 

A pharmaceutical factory licence is renewed annually, and EDE’s GMP compliance certificate is also issued annually. EDE states that a request to renew an EDE-issued GMP certificate can be submitted approximately two months before expiry. Continued GMP compliance is verified through inspection as part of the regulatory requirements.

Does a UAE GMP certificate work for registration in other GCC countries? 

Elsewhere in the GCC, a valid EDE GMP certificate may support the regulatory documentation for a UAE manufacturing site. The Gulf Health Council also operates a central registration framework for pharmaceutical companies and medicines. However, applicable central and country-specific regulatory requirements still need to be assessed for each target market, and a UAE GMP certificate does not provide automatic GCC-wide approval.

What documents does a manufacturing facility need before its GMP inspection? 

Facilities usually need to submit detailed engineering drawings, information on the proposed pharmaceutical forms and production lines, a list of equipment for production and packaging, details on the sterilisation line where applicable, and documentation on the quality control laboratory set-up before a GMP certification inspection is requested. Current EDE requirements also identify information related to estimated water and electricity consumption as part of the construction and preparation stage.

Posted on

PIC/S PI 006-4: What the 2026 Qualification & Validation Update Means for CQV

PIC/S PI 006-4: What the 2026 Qualification & Validation Update Means for CQV

Pharma teams that have been running qualification and validation programmes under the same PIC/S recommendations for years are about to see a significant change in the guidance supporting Annex 15. PIC/S has made a major revision to its Recommendations on Qualification and Validation, PI 006-4, and it comes into effect on 1 October 2026. If your facility is preparing for PIC/S qualification and validation expectations in 2026, be it a new build, an expansion, or an upgrade to an existing plant, this document changes the level of practical guidance available to inspectors and industry.

This post will cover what actually changed with the PIC/S qualification and validation 2026 requirements, why it matters to your CQV programme, and what steps to take before the effective date. We’ll keep it practical and avoid dense regulatory language where possible.

What Is PIC/S Annex 15, and What Just Changed?

Annex 15 is the annex to the PIC/S and EU GMP Guide that sets out the basic principles of qualification and validation in pharmaceutical manufacture. Since its last major revision in 2015, it has remained relatively unchanged. Alongside Annex 15, there is a separate and more detailed recommendations document for inspectors and industry, PI 006. This document provides additional practical guidance in areas where PIC/S identified the need for more detail than Annex 15 provides.

That’s what just changed: that supporting recommendations document. PIC/S has approved a new version, PI 006-4, which supersedes PI 006-3 dated 25 September 2007. The new version takes effect on October 1, 2026, and is a substantial rewrite of the recommendations after nearly 20 years.

Meet PI 006-4: The New Recommendations Document

PI 006-4 is officially entitled PIC/S Recommendations on Qualification and Validation. It’s hard to see why the change is so important, unless you know what it’s replacing. The old PI 006-3 was one document containing individual recommendations covering the Validation Master Plan, installation and operational qualification, non-sterile process validation, and cleaning validation.

PI 006-4 substantially reorganises and expands that material within one updated document. It builds on the 2015 revision of Annex 15. It incorporates quality risk management principles throughout the qualification and validation lifecycle, rather than treating risk assessment as a separate add-on step.

PI 006-4 Significant Additions:

PI 006-4 Significant Additions

Some additions are notable for covering ground the old guidance barely touched:

  • Prequalification stages including the User Requirements Specification (URS), Design Qualification (DQ), Factory Acceptance Testing (FAT) and Site Acceptance Testing (SAT), giving teams more detailed guidance on the planning and verification work that happens before formal IQ, OQ and PQ.
  • Performance qualification in more detail than the older documents provided.
  • Ongoing (or Continued) Process Verification (OPV), extending process monitoring beyond initial validation and across the commercial product lifecycle.
  • Continuous Process Verification (CPV), which PI 006-4 addresses as an alternative approach to initial process validation where appropriate process understanding and control support its use.
  • Transport verification, a gap many facilities have previously filled in an ad hoc way.
  • Packaging validation now has its own dedicated coverage, specifically for solid dose products.
  • Utility qualification, providing more detailed expectations for supporting utilities such as pharmaceutical water, HVAC and process gases.
  • Validation of test methods, with high-level guidance on method validation and verification rather than detailed analytical-method-validation requirements.

The principles in the document apply to the manufacture of active pharmaceutical ingredients, intermediates and finished dosage forms.

Other PI 006-4 Areas CQV Teams Should Not Overlook 

PI 006-4 also places explicit emphasis on data governance throughout qualification and validation and requires data-integrity considerations to be addressed within qualification and validation activities. It includes dedicated coverage of requalification and states that retrospective validation is no longer considered an acceptable approach to process validation. The document also clarifies that validation of GMP-impacting computerised systems remains covered by PIC/S GMP Annex 11 rather than PI 006-4 itself.

Why This Matters for Qualification and Validation Pharma Teams

It is worth clarifying what PI 006-4 is and isn’t. PIC/S refers to it as a guidance and training resource for GMP inspectors and the pharmaceutical industry, rather than the Annex 15 GMP text itself. Annex 15 continues to set out the underlying GMP principles for qualification and validation, while PI 006-4 provides additional practical guidance on how those principles can be applied.

That difference does matter in the field. Just because a facility has validation documentation doesn’t mean that it still stands up to current expectations. The underlying Annex 15 text has not been revised through PI 006-4, but PI 006-4 places much more explicit emphasis on areas such as documented ongoing process verification, supporting utility qualification, data governance and lifecycle control.

What This Means for Your Validation Master Plan

What This Means for Your Validation Master Plan

At the centre of the expanded scope of PI 006-4 is the validation master plan. The older guidance combined VMP requirements with installation and operational qualification without its recommendation, and many facilities perceived this master plan as a static document written once and visited only occasionally.

With the new guidance, this master plan should reflect the full lifecycle perspective that PI 006-4 brings, including qualification, requalification, process validation, ongoing process verification and revalidation activities. Thus, facilities will have to re-examine and revise their VMP to ensure that applicable supporting utilities, qualification and validation activities, requalification requirements and ongoing process verification are appropriately identified or cross-referenced rather than unnecessarily duplicated within the VMP itself.

Importantly, PI 006-4 describes the VMP as a summary document that should remain brief, concise and clear and may refer to existing policies, SOPs, validation protocols and reports.

Impact on Pharma Facility Qualification Timelines

Expanded qualification and validation expectations usually mean additional review and documentation, and documentation takes time to build and review. Facilities planning a pharma facility qualification programme with a completion date around or beyond October 2026 should plan for the additional scope now rather than waiting until an inspection highlights a gap.

This is particularly important for ongoing projects. Facilities that are in the middle of IQ and OQ activities developed against the older recommendations may need to revisit their CQV strategy and protocols to confirm traceability back to the URS and DQ and to ensure supporting-utility qualification is adequately addressed. The approach to ongoing process verification should then be established following initial process validation as part of lifecycle control.

Brownfield Pharma Upgrades Under the New Guidance

There’s a particular wrinkle with this transition for brownfield pharma upgrades. This type of upgrade must reconcile existing qualification and validation status with new expectations, all while production often continues in adjacent areas of the facility, unlike a greenfield project starting with a blank master plan.

Brownfield projects usually have more live interfaces and overlapping disciplines than a similar greenfield build. The plan needs to address the existing structure, ongoing operations, and changed validation and qualification expectations at the same time. 

PI 006-4 specifically calls for qualification and validation planning to consider risks to adjacent or connected operations, as well as risks associated with shared facilities, shared equipment, shared utilities and common HVAC systems. These considerations are particularly relevant to brownfield projects where qualification work may occur alongside ongoing GMP operations. 

Once a facility starts to map its brownfield upgrade against the expanded utility qualification and ongoing verification expectations of PI 006-4, common challenges include ageing HVAC systems, limited utility capacity, and gaps in existing qualification documentation. A team that has done this kind of transition before knows where to look for these gaps early, rather than during an inspection.

Know More : Pharmaceutical Inspection Co-operation Scheme

Steps to Prepare Before the October 2026 Deadline

Here is a practical sequence facilities can use to prepare:

  1. Re-evaluate your current master plan: Map where it already covers qualification, requalification, ongoing process verification, supporting utilities and other applicable PI 006-4 activities, and where there are gaps.
  2. Review existing qualification processes: If you have any projects not yet complete, check that IQ, OQ and PQ activities remain appropriately linked to the URS and DQ and reflect the applicable recommendations in PI 006-4.
  3. Review utility qualification documents: Expectations for supporting utilities such as HVAC, pharmaceutical water and process gases are now addressed in greater detail, so make sure your qualification strategy and records are aligned.
  4. Assess Packaging and Transport Verification Gaps: These are areas now given dedicated coverage in PI 006-4, with the packaging-validation section specifically addressing solid dose products.
  5. Review validation and verification records for test methods: PI 006-4 provides high-level expectations for these activities while recognising that detailed analytical-method-validation guidance exists elsewhere.
  6. Train quality and validation personnel on PI 006-4: Your team should be familiar with the structure and terminology of the document and understand how its recommendations supplement Annex 15.

Why Work with Experienced CQV Services

Managing this transition internally is possible, but it requires coordinated review across quality, validation, engineering and operations. Experienced CQV services can help translate regulatory updates such as PI 006-4 into practical changes to strategies, protocols and qualification activities rather than treating the update simply as a documentation exercise.This is just as important for pharmaceutical CQV work on a new facility as it is for a mid-project upgrade trying to align with the updated recommendations before project completion.

At Pharma Access, our CQV team is involved in greenfield builds, brownfield upgrades, and ongoing qualification projects, covering the entire spectrum from master plan development to IQ, OQ, and PQ execution. Since our engineering and CQV teams begin with the same design intent, validation protocols remain tied to the actual reasoning behind facility decisions, rather than being retrofitted later. 

Wrapping Up

Although PI 006-4 does not itself revise Annex 15, it significantly expands the practical recommendations available for implementing qualification and validation across the lifecycle. Facilities that update their master plan, review in-progress protocols, and address applicable utility, packaging, transport and ongoing-verification gaps well before October 2026 will be in a much stronger position than those scrambling to catch up after the effective date passes.

Know More : Pharmaceutical Inspection Co-operation Scheme

Frequently Asked Questions

What is PI 006-4, and how is it different from Annex 15? 

PI 006-4 is a detailed recommendations document and guidance resource for GMP inspectors and industry. Annex 15 sets out the underlying qualification and validation principles within the PIC/S GMP Guide, while PI 006-4 provides additional practical guidance in areas where PIC/S has identified the need for greater detail.

When does PI 006-4 take effect? 

PI 006-4 becomes effective 1 October 2026. Facilities should plan to review their VMP, CQV strategies and applicable qualification and validation activities against the expanded recommendations by that date.

Does PI 006-4 apply to API manufacturers or only finished dosage forms? 

The principles apply to active pharmaceutical ingredient manufacturing, intermediates and finished dosage forms. However, some individual sections have a narrower scope; for example, the packaging-validation section specifically addresses solid dose products.

How does this affect brownfield pharma upgrades already in progress? 

Any brownfield project currently underway should compare its existing qualification protocols to the expectations in the new document, particularly supporting-utility qualification, risks to adjacent and shared operations, and ongoing process verification, before completing validation work associated with the upgrade.

Do I need to rewrite my entire validation master plan? 

Not necessarily a rewrite, but most facilities should review their VMP to ensure that the qualification and validation lifecycle, requalification, ongoing process verification, supporting utilities and other applicable activities are appropriately covered or cross-referenced. PI 006-4 specifically states that the VMP should be a brief, concise summary document and may refer to other controlled documents rather than repeating their content.

Posted on

Pharmaceutical Plant Layout Design: Types, GMP Flow and Key Considerations

Pharmaceutical Plant Layout Design: Types, GMP Flow and Key Considerations

A pharma plant has a layout decision baked into it before the first wall goes up. The traffic of raw materials, the routes of people, and the movement of air from one room to another all start with one decision made early on in the planning stages: the type of layout the pharmaceutical plant will have.

Make the right choice, and can operate efficiently and reliably for years to come. Get it wrong, and you’re battling cross-contamination risk, bottlenecks, and GMP findings long after construction is complete. A plain language looks at the main layout types, how they stack up, and what really makes the decision.

Why Plant Layout Matters in Pharma

Pharmaceutical plant layout is more than simply placing equipment in a building. It dictates how materials, people, and air move through space, and each of those flows affects product safety. That is something that regulators care about directly. In the US, 21 CFR 211.42(b) requires adequate space for the orderly placement of equipment and materials to prevent mix-ups and contamination, and requires the flow of components, materials and drug products through the building to be designed to prevent contamination. Materials should flow from receipt of raw materials through to manufacturing and then packaging, with unnecessary backtracking and crossovers minimised wherever practical.

That requirement for controlled flow designed to prevent contamination and mix-ups influences almost every other layout decision.

Main Types of Pharmaceutical Plant Layout

Pharmaceutical facilities commonly use three basic layout strategies, often in various combinations, depending on the product mix. In practice, hybrid approaches are also common because different production areas within the same facility may have different process, flow, containment and operational requirements. 

Process (Functional) Layout

A process layout is one in which equipment is grouped according to similar operations. All the mixing vessels are in one area, all the drying equipment in another, etc. The same equipment can be used to run several different products at different times, where product compatibility, cleaning strategy and cross-contamination controls permit shared use. 

This is well suited for plants that make a wide variety of products in smaller quantities. It avoids duplication of expensive equipment, and it provides you flexibility when your production needs change. The downside is more movement between areas, so material handling takes longer, and you need to pay more attention to cross-contamination controls. where product compatibility, cleaning strategy and cross-contamination controls permit shared use. 

Product (Line) Layout

In a product or line layout, equipment is arranged in the exact sequence of the process, from the first operation to the last. The entire product line is on one path.

This is suitable for high-volume production of a single product, for example, a plant with a dedicated tablet production line. Material moves in a straight line, workflow is predictable, and output is easier to plan. The trade-off is less flexibility. If you want to make a different product, the line may require validated changeover, cleaning, additional containment controls or equipment modifications depending on product compatibility; a separate line is not automatically required. Often, the existing equipment can still be used where the process, product characteristics and cleaning strategy allow it.

Cellular Layout

In cellular layout equipment is divided into self-contained cells, each set up to perform a complete set of process steps for a product family. It is between process and product layouts and provides plants with some of the flexibility of a process layout, with some of the flow benefits of a product layout.

This works well for plants that produce a handful of related products, such as different strengths of the same drug, where each cell can be tuned without significantly affecting operations in the rest of the facility.

Single Corridor vs Double Corridor Design

Single Corridor vs Double Corridor Design

The layout type is just part of the picture. Corridor design is another key factor, especially where contamination control, segregation or containment requirements are critical.

  • Single corridor design – one passage may be used for controlled personnel and material movement. It is easier and cheaper to build, but it can become a bottleneck as production volume increases, and it requires careful route planning, access control and operating procedures to minimise undesirable intersections between personnel and material flows.
  • A double corridor design uses two separate circulation routes that can be configured to segregate personnel, materials, waste, clean and used equipment, or service access depending on the facility requirements. This arrangement can be useful in sterile, containment or other higher-risk manufacturing areas where additional segregation is justified, but it is not a universal GMP requirement for these facilities.
  • For sterile facilities specifically, EU GMP Annex 1 requires airlocks for personnel and materials moving between different grades and states that personnel airlocks should, wherever possible, be separated from those used for material movement. Where this is not practical, time-based separation can be considered. This requirement relates to controlled transfer and airlock design and should not be interpreted as a universal requirement for a double-corridor building configuration. https://health.ec.europa.eu/system/files/2022-08/20220825_gmp-an1_en_0.pdf

The Role of HVAC in Pharmaceutical Plant Layout

The Role of HVAC in Pharmaceutical Plant Layout

Layout and air handling cannot be designed independently of each other. Different rooms in a pharmaceutical facility design have different requirements for temperature, humidity, air pressure, and particle count. The HVAC system helps control these conditions according to the classification, process and contamination-control requirements of each room.

HVAC and layout work together in a few ways:

  • Pressure cascades in sterile product-protection areas direct the flow of air from cleaner areas to less clean areas to prevent contamination from flowing backward into a controlled area. Where highly toxic, potent, pathogenic or other hazardous materials require containment, the pressure regime may need to be modified, including the use of negative-pressure or pressure-sink arrangements to protect surrounding areas.
  • Room adjacency is important because it is easier and cheaper to route HVAC ductwork where rooms of similar air classification are adjacent to each other.
  • Airlocks between areas of different classification will be located on the basis of the layout so they are positioned where personnel, materials or equipment cross controlled boundaries.
  • High-potency or sterile zones may require dedicated or segregated air-handling systems depending on product risk, cross-contamination potential, containment requirements and the facility’s contamination-control strategy, so the layout must provide for the necessary mechanical space.

If you skip this coordination, it can show up later as expensive rework, extra ductwork running through finished ceilings, or rooms that cannot consistently achieve their required environmental conditions without redesign.

Factors That Influence Layout Choice

The main factors that normally dictate the layout right for a particular plant are as follows:

  1. Product range: A single, high-volume product can favour a product layout. A mixed portfolio may be better suited to a process, cellular or hybrid layout.
  2. Production volume: A high, steady volume favours a straight-line product layout. Lower, variable volume is better suited to a flexible process layout.
  3. Risk of contamination: High-potency and sterile products require more rigorous segregation and contamination-control or containment strategies. The appropriate pressure regime, airlock configuration and corridor philosophy should be established according to product and process risk.
  4. Space available: On a small site, you may need a more vertical or clustered layout. On a large site, you can be more spread out and linear.
  5. Later expansion: A layout that allows you to add lines or zones later will save you major rework versus one that’s built at full capacity from day one.
  6. Regulatory market: Facilities supplying the US, EU, or other regulated markets require layouts that demonstrate controlled, risk-based material, personnel and product flows and adequate measures to prevent contamination and mix-ups.

Pharmaceutical Facility Design and Construction

The choice of a layout type is only the first step. That choice becomes a working plant by bringing together architecture, process engineering, HVAC, utilities, electrical systems, automation and CQV planning, ideally from the very beginning of the design process, rather than as separate handoffs. Early multidisciplinary coordination helps align equipment integration, room relationships, material and personnel flows, maintenance access and supporting engineering systems.

That is where an integrated pharmaceutical engineering approach becomes important. Pharma Access supports this spectrum, from early layout planning to engineering, procurement, construction and commissioning and qualification, on projects across API, biotech and sterile manufacturing facilities. The layout decision is carried through to the finished building by an integrated project team so the HVAC design, corridor separations, and equipment locations stay aligned rather than being changed piecemeal during construction.

Common Mistakes in Pharma Plant Layout Design

In real projects, some common layout mistakes keep appearing:

  • Choosing a layout type without knowing the product mix: A plant that must later process multiple products can be locked into a product layout, resulting in costly rework.
  • HVAC as a stand-alone project: Air handling has to be part of the layout conversation from the start, not an afterthought once the rooms are already in the layout.
  • Not recognising corridor needs: Often, a corridor designed for a small pilot line cannot handle the traffic when production is ramped up.
  • Ignoring future growth: The compact, fully developed design offers no opportunity to add capacity without major redevelopment.
  • Early elimination of contamination control zoning: Layout has to segregate areas with different contamination-control or containment requirements from day one, rather than trying to correct the zoning strategy after equipment is already installed.

Read More: Turnkey Pharmaceutical Plant in Saudi Arabia

Why Integrated Pharmaceutical Facility Engineering Matters 

Pharmaceutical manufacturing facilities involve increasingly complex requirements across regulated markets. An integrated pharmaceutical engineering team with hands-on layout experience can save a plant from the above mistakes before construction starts. A team that has experience in process, product, and cellular layouts in different dosage forms knows the questions to ask early: product mix, expected volume, target regulatory markets, process risks, containment requirements and future expansion needs.

If you are a pharmaceutical company in India that is looking to build a new facility or expand an existing one, it is generally a smoother build to work with a firm that can manage layout, engineering design, and construction all under one plan, as opposed to dealing with separate vendors for each piece. This is the kind of end-to-end support Pharma Access provides, helping plants take a layout decision and turn it into a facility that performs the way it was designed to.

Wrapping Up

The type of pharmaceutical plant layout a plant uses, be it process, product, or cellular determines everything from the flow of materials to the design of the HVAC system to the ease of future plant expansion. There is no one correct answer. The best layout will depend upon your product mix, production volume, and the regulatory markets you intend to serve. Clarify those factors early, and the layout decision becomes a lot easier to make well.

Frequently Asked Questions

What are the main types of pharmaceutical plant layout?

The three main types are process (functional) layout, product (line) layout, and cellular layout. The process layout groups similar equipment together, the product layout arranges equipment in the order of production, and the cellular layout combines the two. In practice, pharmaceutical facilities may also combine these approaches into a hybrid layout based on the requirements of different process areas. 

Why is unidirectional flow important in pharma plant layout? 

Unidirectional flow means that the materials move through the process in a controlled forward sequence—from raw material toward finished product—with unnecessary backtracking and crossovers minimised. This reduces mix-ups and cross-contamination. In the US, 21 CFR 211.42(b) requires the flow of components, materials and drug products through pharmaceutical buildings to be designed to prevent contamination; it does not universally prescribe one-way movement in every pharmaceutical area.

What is the difference between single and double corridor layouts? 

One corridor may be used for controlled movement of personnel and materials, with appropriate procedures and segregation controls. A double-corridor arrangement uses two separate circulation routes that can segregate personnel, materials, waste, equipment or service movement depending on the facility’s operating philosophy. The additional separation can minimize undesirable crossover and contamination risks, but a double-corridor layout is not universally required for sterile or high-potency manufacturing facilities.

How does HVAC affect pharmaceutical plant layout? 

HVAC helps control the air pressure, temperature, humidity and airborne particulate conditions in each room. HVAC planning should occur alongside layout planning, not after, because layout decisions affect how easily pressure cascades can be achieved and how ductwork can be routed. The pressure strategy should also reflect whether the primary objective is product protection, containment, or both.

Which layout type is best for a new pharma plant? 

It depends on your product portfolio. Typically, a plant that produces a single product in large quantities is suited to a product layout; a plant that produces multiple products tends to be suited to a process or cellular layout. In many cases, a hybrid layout provides the most practical solution by applying different layout principles to different areas of the facility.

Posted on

HPAPI Facility Design: How to Plan Containment by OEB Level

HPAPI Facility Design: How to Plan Containment by OEB Level

If your team is building or upgrading a plant to handle highly potent active pharmaceutical ingredients, containment is the first thing you need to get right. Late or incorrect containment decisions can create operator exposure risks, inspection findings, and costly rework after the building is already under construction. Get it right and you have a facility that protects people, supports global regulatory expectations, and runs with stable, controlled operations.

This post walks through HPAPI facility design in plain language, with a focus on Occupational Exposure Limits (OELs), Occupational Exposure Bands (OEBs) and how they guide every containment decision you make, from room layout to equipment selection and performance verification.

What Is an HPAPI, and Why Does Containment Matter?

A highly potent active pharmaceutical ingredient, or HPAPI, is a drug substance with high pharmacological or toxicological activity at low exposure levels. Think potent oncology compounds, certain hormones, cytotoxic APIs and highly active small-molecule intermediates. Because these materials can be active or harmful at very low exposure levels, even a tiny amount of airborne dust or residue can affect an operator’s health over time.

Here is why this matters for facility design: conventional API plants are built around cleanliness, product protection and worker safety. HPAPI plants require an additional, more stringent goal, protecting the people who work in them while also controlling cross-contamination. That additional goal drives decisions about room pressure, airflow, equipment type, and even how waste and gowning are handled.

What Is an Occupational Exposure Band (OEB)?

Before you design anything, you need to know the compound’s toxicological potency and the exposure level that must be controlled. That is what OEL development and Occupational Exposure Banding help establish. An OEL is a compound-specific airborne exposure limit, commonly expressed as an eight-hour time-weighted average, while an OEB groups compounds within an exposure range and can support decisions when a sufficiently robust compound-specific OEL is not yet available. 

Many pharmaceutical companies use five-band systems, but the numerical limits and band definitions are not globally standardized. At one end, OEB 1 generally covers materials with higher airborne exposure ranges and simpler control needs. At the other end, OEB 5 covers the most potent compounds, with occupational exposure limits below 1 microgram per cubic meter, often in the nanogram range.

It is also important not to use OEL/OEB and PDE/ADE interchangeably. OELs and OEBs support worker protection, while Permitted Daily Exposure (PDE) or Acceptable Daily Exposure (ADE) values are health-based limits used mainly to assess patient risk from cross-contamination and to establish cleaning limits in shared manufacturing facilities.

A simplified way to look at the bands is shown below. These ranges represent an illustrative five-band pharmaceutical scheme and should not be treated as a universal regulatory standard:

  • OEB 1: Higher exposure range, generally 1,000 µg/m³ or above. Good industrial hygiene, suitable ventilation and basic source controls may be sufficient, subject to a task-specific assessment.
  • OEB 2: OEL roughly 100 to below 1,000 µg/m³. Downflow booths, local exhaust ventilation or dust-controlled connections may be used depending on the operation.
  • OEB 3: OEL roughly 10 to below 100 µg/m³. Greater enclosure, glove bags, flexible isolators and closed transfer systems may be required based on the task.
  • OEB 4: OEL roughly 1 to below 10 µg/m³. High-performance primary containment, such as rigid isolators or an equivalent demonstrated system, is often considered.
  • OEB 5: OEL below 1 µg/m³, sometimes extending below 0.1 µg/m³. Very high containment, robust transfer, cleaning, maintenance and verification controls are required, with an isolator or equivalent demonstrated system selected according to the operation.

Your OEL or OEB assignment is not a guess. It comes from an evaluation of the compound’s toxicological potency and the health effects tied to exposure, usually done by a qualified occupational toxicologist or industrial hygienist before the design team finalizes the concept. The final containment strategy also considers process scale, quantity handled, dustiness, task duration and frequency, cleaning, maintenance and potential dermal exposure.

How OEB Levels Shape HPAPI Facility Design

How OEB Levels Shape HPAPI Facility Design

Once you know the OEL or applicable OEB, the design choices can follow a risk-based pattern, but the band alone does not prescribe a specific technology. Here is how it may play out at each stage.

OEB 1 and 2: Basic Engineering Controls

At the lower bands, the room design stays fairly close to a normal API facility. You still need good airflow, an appropriate ventilation and pressure strategy where required, and proper gowning procedures. The main additions may include local exhaust points at material transfer stations and dust-tight connections for charging and discharging powders.

OEB 3: Isolators and Closed Transfers

This is often the point where a plant moves from basic source control toward greater enclosure and contained transfer, although the exact solution depends on the task. Glove bags and flexible isolators may start showing up around reactors, dryers, and milling equipment. Room pressure cascades become more carefully coordinated rather than simply tighter, and airlocks with interlocks may be used according to the risk assessment between the process area and the corridor.

OEB 4 and 5: Full Containment

At OEB 4 and especially OEB 5, primary containment equipment and the supporting facility controls become more demanding. You are looking at rigid isolators or equivalent demonstrated systems, split butterfly valves for material transfer, dedicated or appropriately segregated air handling where required by risk assessment, suitable exhaust treatment and safe-change filtration where necessary, and monitoring of critical pressure and ventilation parameters.

Occupational hygiene sampling and containment-performance testing are then used to demonstrate that exposure remains below the defined target before routine production begins.

Steps to Plan an HPAPI Facility

Validate before startup

Here is a practical order of operations for teams starting from scratch:

  1. Get the toxicology data first: You cannot design containment without knowing the OEL or applicable OEB and other relevant health hazards of the compound you plan to make.
  2. Map the process flow: Identify every point where the material is open to the room, such as charging, sampling, and packing, as well as cleaning, filter changes, maintenance and waste handling.
  3. Match the containment strategy to the OEL/OEB and task risk: Assign the right level of isolator, glove bag, or booth to each open point based on the exposure target, quantity, dustiness, duration, frequency and demonstrated containment performance.
  4. Design the room around the equipment, not the other way around: The pressure strategy, airlocks, and material and personnel flow should support the containment devices you have chosen.
  5. Plan for cleaning and decontamination: Every HPAPI area needs a documented method for appropriate dry or wet cleaning, decontamination, cleaning verification and safe waste removal. Product carryover limits should be based on the applicable HBEL/PDE/ADE, while occupational surface contamination should be assessed separately.
  6. Validate before startup: Run containment-performance testing using a surrogate powder and an established methodology such as SMEPAC on equipment to confirm it meets the defined containment-performance target before routine production begins.
  7. Train operators and maintenance personnel on the specific hazard: Generic gowning training is not enough at OEB 4 or 5. People need to understand what they are protecting against and why, including the requirements for cleaning, spill response, waste handling and actions following a containment breach.
  8. OEB classification addresses occupational health exposure, but it does not replace separate assessments for dermal exposure, sensitization, solvent hazards, chemical reactivity, static electricity or combustible dust. These risks need their own process-safety and industrial-hygiene controls. 

Building a Pharma Manufacturing Base With Containment in Mind

Many companies expanding into HPAPI production are not starting with a blank site. They are adding a containment suite to an existing plant, or converting part of a conventional API building. This is where planning early pays off. Retrofitting containment into a building that was not designed for it can require significant redesign, new HVAC interfaces and additional shutdown work.

When you are building a pharma manufacturing base that includes HPAPI capacity, a few things help keep the project on track:

  • Bring in OEL and OEB input before the architectural layout is locked.
  • Use dedicated or appropriately segregated HVAC strategies for high-containment zones, and justify any recirculation or exhaust arrangement through risk assessment.
  • Design corridors and airlocks with the material, waste and gowning flow in mind, not just square footage.
  • Plan utility routing (process gases, nitrogen, vacuum, clean compressed air, heating and cooling media, and the required water grade) around the containment equipment early, since retrofitting piping through a sealed isolator room later can create significant design and construction interfaces.

Firms that specialize in pharmaceutical engineering and containment integration often bring this experience to a project because they can coordinate equipment, facility, HVAC, utilities, cleaning and CQV interfaces together. Pharma Access works across engineering design, procurement and supplies, construction and installation, project management and CQV for pharmaceutical facilities, helping coordinate containment-related requirements with the wider facility design from the start.

Common Mistakes in HPAPI Facility Design

A few mistakes show up again and again on HPAPI projects:

  • Assigning the OEL or OEB too late: If toxicology data comes in after the layout is fixed, you end up retrofitting containment into a space that was not built for it.
  • Treating all HPAPIs the same way: An OEB 3 compound does not automatically need a containment solution intended for a much lower exposure range, and over-designing wastes money without adding real protection.
  • Ignoring the cleaning and decontamination strategy during design: If a room cannot be cleaned and decontaminated properly, cross-contamination risk goes up no matter how good the containment equipment is.
  • Underestimating airflow and pressure cascade design: A single poorly placed door or airlock can disrupt the intended airflow direction and weaken the facility’s secondary containment strategy.
  • Skipping operator training on the specific compound: Equipment only works as well as the people using it.

Why Work With Pharma Consultants in India

HPAPI manufacturing has created a growing need for pharma consultants who understand both global regulatory expectations and local construction realities. Working with a consultant who has handled containment integration before can reduce back-and-forth with equipment vendors and help resolve design interfaces earlier.

Full-service pharma project management services matter here too, since HPAPI projects touch process engineering, HVAC, architecture and civil work, automation, and CQV all at once. Coordinating these pieces without a single point of accountability can create interface gaps and delay decisions. 

Pharma Access provides integrated support across engineering design, procurement and supplies, construction and installation, project management and CQV, which is important on containment-heavy projects where systems and interfaces need to be coordinated from concept design onward.

Wrapping Up

HPAPI facility design comes down to more than one question at every stage: what is the OEL or applicable OEB of this compound, where can exposure occur, and do the room, the equipment, the cleaning systems, the transfer systems and the airflow around it match that hazard level? Get the toxicology data early, match your containment strategy to the actual exposure target and task risk, and build the room around the equipment rather than squeezing equipment into a fixed room later. That order of operations is what supports predictable HPAPI project delivery and, more importantly, keeps the people working in the facility safe.

Frequently Asked Questions

What does OEB mean in pharma facility design? 

OEB stands for Occupational Exposure Band. It’s a classification system that groups drug compounds within airborne exposure ranges using toxicological and health-effect information. It can support containment decisions, particularly when a sufficiently robust compound-specific OEL is not yet available, but it does not directly prescribe a particular containment technology.

What is the difference between an OEL and an OEB?

An OEL is a compound-specific airborne exposure limit. An OEB is a range used to group compounds according to toxicological potency or a corresponding exposure-control range. Where sufficient data are available, the compound-specific OEL provides the more precise target. 

How many OEB levels are there? 

Most pharma companies use a five-band system, OEB 1 through OEB 5. However, OEB schemes are company-specific and are not globally standardized. Some systems use numbers, while the NIOSH occupational exposure banding system uses bands A through E.

Do all HPAPI facilities need isolators? 

Not always. Lower exposure-risk operations may only need local exhaust ventilation or downflow booths. Isolators or equivalent high-performance containment systems may be required for lower exposure targets, but the selection should also consider the process, quantity, dustiness, duration, cleaning, maintenance and demonstrated equipment performance.

How early should containment planning start in a facility project? 

As early as possible, ideally before the architectural layout is finalized. Toxicology data and the OEL or applicable OEB assignment should come first, since they help determine room pressure, airflow design, material transfer, cleaning requirements and equipment choices later in the project.

What is the difference between an API facility and an HPAPI facility? 

A standard API facility focuses on product quality, cleanliness and worker safety. An HPAPI facility requires more stringent occupational-exposure and cross-contamination controls, which can mean added containment equipment, sealed transfer systems, specialized cleaning and waste-handling strategies, and dedicated or appropriately segregated air handling.

What is the difference between an OEL and a PDE/ADE?

An OEL is used to protect workers from occupational exposure, usually through an airborne concentration limit. A PDE or ADE is used mainly to assess patient risk from cross-contamination and to support cleaning-limit decisions in shared manufacturing facilities. The values address different exposure scenarios and should not be used interchangeably.

Posted on

EU GMP Annex 1: Designing Compliant Sterile Facilities

EU GMP Annex 1: Designing Compliant Sterile Facilities

If your facility manufactures sterile products, EU GMP Annex 1 is probably the single document that shapes the most decisions on your design drawings. It touches your cleanroom layout, your air handling, your gowning rooms, and even how you validate filters. Getting it right at the design stage saves you from expensive rework once construction is already underway.

This post breaks down what the guideline actually requires, what changed in the 2022 revision, and what that means for how sterile facilities get designed and built today.

What Is EU GMP Annex 1?

EU GMP Annex 1 is the section of the European Union’s Good Manufacturing Practice guidelines that covers the manufacture of sterile medicinal products. It sits within EudraLex Volume 4 and sets out the expectations for cleanroom design, contamination control, aseptic processing, and environmental monitoring.

The annex was first published in 1971, but it went through a major rewrite that was finalized by the European Commission in August 2022 and came into operation on 25 August 2023, except for paragraph 8.123, which came into operation on 25 August 2024. This was the first full revision of Annex 1 following several partial revisions, and it substantially expanded the guideline, reflecting how much more detail regulators now expect from sterile manufacturers. 

Why the 2022 Revision Changed So Much

Here is the shift worth understanding. The older version of Annex 1 leaned more heavily on prescriptive requirements and did not define the same holistic, risk-based contamination-control framework.The revised version asks manufacturers to prevent contamination before it happens, through a documented, facility-wide approach called a Contamination Control Strategy (CCS).

A few things stand out about this revision:

  • It was developed jointly by the PIC/S and EMA Inspectors’ Working Group, in close cooperation with the European Commission and WHO, so the expectations now line up closely across EU, PIC/S, and WHO sterile-manufacturing guidance.
  • It applies a Quality Risk Management approach, meaning contamination controls need to be built into the facility and process from the start, not bolted on afterward.
  • Grade A areas now carry a stricter viable contamination limit, stated as “No growth,” with any microbial growth requiring an investigation.

The Contamination Control Strategy (CCS): The Core Requirement

The Contamination Control Strategy (CCS): The Core Requirement

If there is one concept to understand about this guideline, it is the CCS. A Contamination Control Strategy is a documented, facility-wide strategy that may reference several connected systems and explains how a facility identifies, prevents, detects, monitors, and controls contamination risks across the entire production process.

The CCS is not a paperwork exercise you complete after the facility is built. It needs to cover:

  1. Facility and equipment design. How the layout, airflow, and material flow reduce contamination risk from the ground up.
  2. Personnel practices. Gowning procedures, movement patterns, and training that limit human-sourced contamination.
  3. Environmental monitoring. Ongoing particle and microbial monitoring that provides evidence that the facility continues to perform as intended, not just on the day it was qualified.
  4. Process controls. Aseptic technique, filter integrity testing, and sterilization validation tied directly to the risk profile of each product.

The CCS should also address utilities, raw materials, product containers and closures, supplier and outsourced-activity controls, cleaning and disinfection, preventive maintenance, sterilization, process validation, CAPA, trend analysis, and continual improvement. 

Because the CCS spans design through operation, it has to be considered from the earliest facility planning stage, not added as a compliance document once construction wraps up.It should also be actively reviewed and updated where appropriate, with its effectiveness forming part of periodic management review. 

Cleanroom Grades Under the Guideline

The annex defines four cleanroom grades, A through D, based on particle and microbial limits. Each grade maps to a different level of risk in the manufacturing process.

  • Grade A: The critical zone. This covers aseptic filling lines, stopper bowls, open primary packaging, and any point where the product or its containers are directly exposed. First-air protection and appropriate airflow must be demonstrated over exposed sterile products, components, and critical surfaces. Unidirectional airflow is required for conventional Grade A zones, RABS, and open isolators, while airflow may not be fully unidirectional in closed isolators used for simple operations.
  • Grade B: The background environment surrounding Grade A operations where an isolator is not used. Aseptic RABS normally require at least a Grade B background, while open isolators generally require at least Grade C and closed isolators at least Grade D, based on risk assessment and justification within the CCS.
  • Grade C and D: Support areas for lower-risk stages, such as preparing solutions or components before they move into higher-grade zones. They can also be used for the preparation or filling of terminally sterilized products, depending on the operation and assessed risk.

Getting the grading right at the design stage determines nearly everything else downstream, from HVAC sizing to how many airlocks and gowning stages your layout needs.

The choice between terminal sterilization and aseptic processing should also be established early. Annex 1 expects finished products to be terminally sterilized wherever possible because a validated and controlled terminal sterilization process provides greater sterility assurance than sterile filtration or aseptic processing alone. This decision directly affects cleanroom grades, equipment selection, material flows, and the overall facility layout. 

Designing a Facility Around the Guideline From Day One

A common mistake is treating the annex as a testing checklist to satisfy near the end of a project. The revision makes clear that contamination control has to start on the drawing board.

A few design principles carry real weight under the current guidance:

  • Early barrier-technology evaluation: The annex places heavy emphasis on separating personnel from the product, requiring RABS, isolators, robotic systems, and other appropriate technologies to be considered to maintain the required conditions with less reliance on human intervention.
  • Airflow modeling before construction: Using CFD and design-stage airflow studies to assess unidirectional airflow patterns and pressure cascades on paper, before pouring concrete, can help identify potential dead zones before the room is built. Airflow predictions must then be verified through physical airflow visualization studies during qualification, both at rest and in operation, including representative interventions, while pressure relationships must be verified through qualification testing and monitoring.
  • Material and personnel flow separation: Layouts need clear, risk-based paths that minimize crossing and backtracking for people, materials, and waste to prevent contamination between clean and less-clean zones. Separate personnel and material airlocks should be provided wherever practicable, with unidirectional transfer arrangements used for materials entering and leaving Grade A and B areas. Where complete physical separation is not possible, risk-assessed time separation and procedural controls should be established.
  • Built-in monitoring points: Continuous total-particle monitoring during critical processing and continuous viable air monitoring in Grade A, with a similar risk-based approach considered for Grade B, need sensor and sampling locations designed into the room, not retrofitted later.

An integrated pharmaceutical engineering design approach brings these principles together at the concept and detailed design stage, so the facility’s physical layout supports the CCS instead of working against it.

Where CQV Services Fit Into Compliance

Where CQV Services Fit Into Compliance

Design intent only matters if it can be proven. This is where CQV services for pharmaceutical facilities become part of the compliance story, not a separate afterthought. Commissioning confirms the systems work as installed. Qualification, beginning with Design Qualification and continuing through IQ, OQ, and PQ, provides documented evidence that the design is suitable, the systems are correctly installed, and the facility operates and performs as intended. Qualification, validation, environmental-monitoring trends, deviation investigations, and CAPA tie it all together with documented evidence that the controls defined within the CCS remain effective under routine production conditions. 

Under the revised guideline, this evidence chain matters more than ever. Regulators expect to see aseptic process simulation records for aseptic processes, installed HEPA filter integrity test records, sterilizing-grade process-filter integrity test records where sterile filtration is used, and environmental-monitoring trend data that support the effectiveness of the controls described in the CCS. A facility that cannot produce this evidence, regardless of how well it was designed, will have difficulty demonstrating an effective state of control during inspection.

Common Pitfalls Facilities Run Into

A few issues show up again and again when facilities try to retrofit compliance instead of designing for it from the start:

  • Underestimating airlock and gowning requirements, which forces awkward layout changes mid-construction.
  • Treating the CCS as a document exercise instead of a living strategy tied to actual facility operation and monitoring data.
  • Skipping early filter and barrier technology decisions, which then constrain HVAC and room layout choices later in the project.
  • Insufficient personnel flow separation, leading to cross-contamination risks that only surface during environmental monitoring after startup.

Why Local Expertise Matters for Global Compliance

This EU guideline sets a widely used international benchmark, but applying it correctly depends heavily on local construction practices, climate conditions, and regulatory context. Working with experienced pharmaceutical engineering consultants in India means your facility design accounts for both the international standard and the practical realities of building and operating in your specific market.

Pairing that engineering expertise with project-specific input from quality, microbiology, and regulatory specialists who understand how EU, PIC/S, and WHO guidance is applied gives a facility a stronger position going into its first audit, rather than discovering gaps after the fact.

At Pharma Access, our engineering design and CQV teams work on sterile facility projects that need to meet this standard from the concept stage through validation. We handle cleanroom design, HVAC, utilities, monitoring requirements, and commissioning through one coordinated engineering and qualification approach, which helps facilities avoid the costly redesigns that come from treating contamination control as an afterthought. You can learn more about our approach on the Pharma Access about page.

Wrapping Up

The guideline asks manufacturers to think about contamination control as a design principle, not a final inspection hurdle. A facility built around a well-developed Contamination Control Strategy, with cleanroom grades, barrier technology, and monitoring points planned from the start, is better positioned to demonstrate consistent performance during qualification and maintain control over time. The earlier this thinking enters the design process, the less it costs to get right.

FAQs

What is the main change in the 2022 revision of EU GMP Annex 1? 

The revision strengthens the move away from relying on monitoring or end-product testing alone and toward a proactive, risk-based Contamination Control Strategy that covers facility design, personnel practices, and ongoing monitoring together.

What is a Contamination Control Strategy (CCS)? 

A CCS is a documented, facility-wide strategy that may reference several connected systems and explains how contamination risks are identified, prevented, detected, monitored, and controlled, spanning facility design, equipment, personnel, and monitoring, throughout the entire production process.

What are the cleanroom grades under this guideline? 

The annex defines Grades A through D. Grade A is the critical zone with the strictest limits, Grade B normally the background for Grade A aseptic processing where an isolator is not used, and Grades C and D support lower-risk stages of production. RABS and isolator background grades depend on the selected technology, process risk, and justification within the CCS.

Does this guideline only apply to EU-based manufacturers? 

No. EU GMP Annex 1 applies to sterile medicinal products manufactured under EU GMP requirements, including products manufactured outside the EU for supply to the EU or EEA market. PIC/S Annex 1 and WHO sterile-manufacturing guidance are closely harmonized with the EU text, but manufacturers must still consider the specific legal and regulatory requirements of every target market. 

When should compliance be considered during a facility project? 

From the earliest design stage. Retrofitting cleanroom grading, airflow, or barrier technology after construction is far more costly than building the Contamination Control Strategy into the original layout.

Note: This article provides a general engineering interpretation of EU GMP Annex 1. It should be read together with the official guideline and should not replace project-specific quality, microbiological, or regulatory assessment. 

Posted on

Types of Purified Water Generation Systems in the Pharmaceutical Industry

Types of Purified Water Generation Systems in the Pharmaceutical Industry

Water is used throughout pharma manufacturing. It goes into formulations, cleans equipment, and rinses containers before they ever touch a product. Because of that, a purified water generation system in pharmaceutical industry settings is not a side utility. It is a quality-critical utility that requires careful design, qualification, monitoring, and control.

This post breaks down the common types of purified water systems, how they work, and how to pick the right setup for your facility. We will keep things simple and skip the deep engineering jargon where we can.

What Counts as Purified Water in Pharma?

Purified water is water treated to remove dissolved solids, organic matter, and microorganisms until it meets pharmacopeial standards. Pharmacopeias such as USP, Ph. Eur., and IP establish requirements and guidance for pharmaceutical water quality. For USP Purified Water, chemical attributes such as conductivity and Total Organic Carbon (TOC) are compendial requirements, while microbiological quality is addressed through appropriate monitoring and system-specific control rather than a microbial limit within the Purified Water monograph itself.

Here is why that matters. Ordinary tap or ground water carries suspended solids, dissolved salts, organic compounds, and microbes that can throw off a formulation or fail a batch release test. A pharmaceutical facility generally uses water meeting applicable drinking-water requirements as the minimum feedwater for Purified Water generation, with further treatment applied to achieve the required pharmaceutical water quality.

The Two-Stage Approach: Pretreatment and Final Purification

The Two-Stage Approach: Pretreatment and Final Purification

Most purified water generation trains can be understood through two main treatment stages, and understanding this split makes the rest of this guide easier to follow. After generation, storage, distribution, sanitization, and monitoring become equally important for maintaining the required water quality up to the point of use.

Stage 1: Pretreatment

Pretreatment removes the large stuff first, so it does not damage sensitive equipment downstream. This stage may include multi-media filters, activated carbon filters, and water softeners to strip out particles, chlorine, and hardness before the water moves any further. The actual pretreatment sequence depends on feedwater quality and the requirements of the downstream purification system. 

Stage 2: Final Purification (Polishing)

The final treatment stage, sometimes called polishing, brings the water down to the target purity level often through reverse osmosis followed by electrodeionization where appropriate to further lower conductivity before storage. Additional steps such as UV treatment or ultrafiltration may be added depending on what the facility needs.

Common Types of Purified Water Generation Systems

Here are the main system types you will run into in pharma manufacturing.

1. Reverse Osmosis (RO) System

RO uses pressure to push water through a semipermeable membrane, rejecting a high proportion of dissolved salts, many organic contaminants, particulates, and microorganisms. It is often the workhorse of a purified water system because it can substantially reduce multiple contaminant classes in a single treatment stage.

2. Deionization (DI) System

DI systems pull ions out of water using resin beds charged to attract dissolved minerals. On their own, DI systems may be used within qualified pharmaceutical water-treatment trains, although they are often combined with other purification technologies rather than relied upon as the only treatment barrier.

3. Electrodeionization (EDI) System

EDI combines ion-exchange resins with ion selective membrane and  electric current to continuously remove dissolved ions without the chemical regeneration that older DI systems needed. An EDI module usually sits right after the reverse osmosis stage, where it removes residual ionic contaminants from RO permeate to help achieve the required conductivity. This is a big reason RO+EDI has become a common configuration in modern pharmaceutical Purified Water systems. 

4. Distillation System

Distillation boils water and collects the condensed steam, leaving contaminants behind. It remains a well-established technology for Water for Injection (WFI) production. Current pharmacopeial frameworks also permit appropriately designed and qualified non-distillation purification processes for WFI production. 

5. Ultrafiltration (UF) System

UF uses a membrane process designed primarily to retain microorganisms, colloids, macromolecules, and, in appropriately designed applications, reduce endotoxin burden rather than remove dissolved ions. It is often added at the end of a system when additional microbial, colloidal, or endotoxin control is required. It is not primarily a conductivity-polishing technology, and TOC measurement should not be treated as a substitute for microbiological or endotoxin control.

6. Hybrid Systems (RO + EDI)

Hybrid systems combining reverse osmosis and electrodeionization are widely used to achieve pharmaceutical Purified Water quality, with RO+EDI offering continuous ionic polishing without routine chemical regeneration of conventional ion-exchange resin beds. If you are specifying a new system today, this is often one of the configurations evaluated first, although the final treatment sequence should always depend on feedwater quality, required water quality, capacity, sanitization strategy, and operating requirements.

Purified Water vs. Water for Injection (WFI)

Purified Water vs. Water for Injection (WFI)

A quick point of confusion worth clearing up: purified water and WFI are not the same thing. Purified water is commonly used for non-parenteral formulations, equipment cleaning, and other applications where PW is the specified grade, while WFI is required for applications such as the manufacture of injectable products and specified final-rinse operations associated with injectable product-contact equipment and components. WFI also includes a bacterial endotoxin requirement and requires an appropriate microbiological control strategy. Choosing the right system depends heavily on which one your product line actually needs.

How HVAC Ties Into Water System Performance

A purified water system does not operate in isolation. The room housing it, along with the surrounding manufacturing areas, depends on properly functioning HVAC to control temperature, humidity, and other environmental conditions required for equipment, instruments, and manufacturing operations. HVAC supports the operating environment around the utility system, although water quality itself is primarily controlled through hygienic system design, circulation, sanitization, storage, and distribution.

This is where HVAC validation in pharmaceutical industry projects becomes relevant. HVAC qualification may include, as appropriate, design qualification (DQ), installation qualification (IQ), operational qualification (OQ), and performance qualification (PQ). Testing during this process may cover air changes per hour, airflow pattern and velocity, pressure differentials, temperature and humidity, filter leak testing, and particle counts, with the scope determined based on the facility, application, and risk assessment.

Poor HVAC control in a classified or controlled manufacturing area can undermine the environmental conditions required by the process. However, maintaining Purified Water quality still depends primarily on the design and operation of the water generation, storage, and distribution system rather than HVAC alone.

Monitoring and Control: The Role of a Building Management System

Modern pharma facilities do not run water and HVAC systems on manual checks alone. A pharmaceutical water system is commonly monitored and controlled through dedicated automation such as PLC/HMI or SCADA architecture, while BMS or EMS platforms may integrate selected facility and utility information depending on the overall control philosophy. 

A well-set-up automation and monitoring architecture gives your team real-time visibility into pressure, temperature, water-system parameters, operating status, and system alarms, so problems get caught before they turn into a failed batch or a finding during inspection. Where appropriate, selected water-system status and alarms may also be integrated into the facility BMS or supervisory platform, reducing the need for operators to rely on separate systems for basic utility visibility.

Choosing the Right System for Your Facility

A few questions can help narrow down which purified water generation system in pharmaceutical industry settings fits your operation:

  1. What is your feed water quality? Hard, high-mineral water needs heavier pretreatment before RO.
  2. What product types do you manufacture? Non-parenteral products commonly use Purified Water where it is the specified grade, while injectable formulations typically require WFI for formulation and certain final-rinse applications.
  3. What is your daily water demand? Higher volumes influence generator capacity, redundancy, storage volume, and lifecycle economics, but technology selection must still begin with the required water grade and quality specification.
  4. What are your TOC and conductivity targets? Conductivity requirements influence technologies such as RO and EDI, while UV, UF, or other treatment steps may be selected for specific organic, microbial, or endotoxin-control objectives depending on the system design.
  5. How will you sanitize the system? Hot water sanitizable skids reduce chemical use but need membranes, EDI modules, seals, instrumentation, and other system components rated for that heat.

Why Facility Design Matters as Much as Equipment Choice

Why Facility Design Matters as Much as Equipment Choice

Buying the right skid is only part of the job. Piping layout, storage tank design, and distribution loop configuration all affect whether purified water stays within spec between the generation point and the point of use. A poorly designed loop can allow stagnant conditions that encourage microbial proliferation, even with a solid generation system upstream. Hygienic design therefore also considers factors such as dead-leg minimization, drainability, appropriate tank design, circulation, sanitization, sampling points, and monitoring.

This is where working with experienced pharmaceutical utility engineers and consultants pays off. At Pharma Access, our engineering design team handles mechanical and utility system design, including water and HVAC systems, as part of full facility projects across India and other markets. We look at generation, storage, distribution, and the supporting facility systems as coordinated engineering packages instead of isolated design scopes, helping reduce the coordination gaps that can cause rework later. You can see more about how we approach clean utility systems, including Purified Water and WFI, on the Pharma Access Clean & Black Utilities.

Wrapping Up

There is no single “best” purified water system for every pharma facility. RO+EDI is a widely used configuration for pharmaceutical Purified Water generation, while WFI can be produced through distillation or appropriately designed and qualified non-distillation processes where permitted by the applicable pharmacopeial and regulatory framework. What matters most is matching the system to your feed water, your product line, and your validation plan, then backing it with hygienic storage and distribution, an appropriate sanitization strategy, monitoring, and integration with the wider facility utility and control systems.

FAQs

What is the most common purified water system used in pharma today? 

RO combined with EDI is one of the commonly used configurations for modern pharmaceutical Purified Water systems. It removes most contaminants through the RO stage and then uses electrodeionization to remove residual ionic contamination and achieve the required conductivity without routine chemical regeneration of conventional DI resin beds.

What is the difference between purified water and Water for Injection (WFI)? 

Purified water supports applications such as non-parenteral formulations and cleaning where PW is the specified grade. WFI is used for applications including injectable-product manufacture and specified final-rinse operations and includes a bacterial endotoxin requirement.

How often should a purified water system be validated? 

Most facilities qualify the system before routine use through defined lifecycle activities that include IQ, OQ, and PQ as applicable, followed by ongoing monitoring, trending, maintenance, change control, periodic review, and risk-based requalification where required. There is no single universal requalification interval that applies to every pharmaceutical water system.

Does HVAC really affect purified water quality? 

Indirectly, yes. HVAC maintains appropriate environmental conditions around equipment and manufacturing areas, but Purified Water quality is primarily maintained through hygienic water-system design, circulation, sanitization, storage, distribution, and monitoring.

Can one system handle both purified water and WFI needs? 

A facility may share elements of upstream feedwater or pretreatment infrastructure, but PW and WFI generation, storage, distribution, sanitization, and monitoring strategies must be designed according to their respective quality requirements and intended applications. The final system architecture should therefore be established through process requirements, applicable pharmacopoeias, and a documented risk-based design approach.

Posted on

ICH Q13 Continuous Manufacturing: What It Means for Facility Design

ICH Q13 Continuous Manufacturing

If your plant is moving from batch production to continuous manufacturing, the facility design itself may need to change, not just the equipment inside it. ICH Q13 is the guideline that sets out the scientific and regulatory considerations for how continuous manufacturing (CM) should be developed, implemented, operated, and managed over its lifecycle. For anyone planning a new facility or converting part of an existing one, these principles can influence decisions long before the first piece of equipment gets installed. 

This post breaks down ICH Q13 in plain terms and walks through what it actually means for facility layout, automation, and day-to-day operation.

What Is Continuous Manufacturing?

In a batch process, you make a defined quantity of product and move it through manufacturing steps as a batch. Continuous manufacturing works differently. Materials are continuously fed into the process, transformed as they move through it, and output material is removed while the process is operating.

The guideline describes CM as the continuous feeding of input materials, transformation of in-process materials, and simultaneous removal of output materials from the manufacturing process. That single concept explains why facility design changes so much under CM. The facility is no longer planned only around a series of isolated processing steps. It’s planned around how connected operations interact and how material moves through the system.

Importantly, ICH Q13 makes clear that continuous manufacturing can apply to some or all unit operations. A manufacturing process can therefore combine batch operations with directly connected continuous operations rather than requiring the entire process to operate continuously.

What Is ICH Q13?

ICH Q13 is a guideline from the International Council for Harmonisation that covers the science and regulatory expectations behind continuous manufacturing of drug substances and drug products. Work on it began in 2018, a draft was endorsed for public consultation in July 2021, and the final Step 4 guideline was adopted on November 16, 2022. In the EU, the guideline became legally effective on July 10, 2023. The FDA issued its final Q13 guidance for industry in March 2023.

The guideline builds on earlier ICH quality guidelines such as Q8 (Pharmaceutical Development), Q9 (Quality Risk Management), Q10 (Pharmaceutical Quality System), and Q11 (Development and Manufacture of Drug Substances). It also includes a dedicated section, Annex III, that covers continuous manufacturing of therapeutic protein drug substances. The guideline also notes that its broader principles may apply to other biological and biotechnological entities.

At its core, the guideline addresses process development, control strategy, process dynamics, equipment design and system integration, process monitoring and control, process validation, and lifecycle management, all under one connected approach.

How ICH Q13 Shapes Facility Design

How ICH Q13 Shapes Facility Design

Here is where the guideline turns into real construction and layout decisions.

  • Equipment footprint can shrink, but connections multiply: CM system design can enable process simplification or intensification and, in some cases, reduce the number or size of unit operations, although a smaller facility footprint is not guaranteed. Integrated equipment also has to connect and interact as a system, which means piping, transfer interfaces, instrumentation, sensors, control cabling, and maintenance access need careful planning from the start.
  • Process monitoring becomes part of the room design: Where Process Analytical Technology (PAT), in-line, on-line, or other process measurements are used, the facility needs suitable instrument locations, power, data connectivity, sampling access, and maintenance access built in rather than added later. PAT is well suited to CM under ICH Q13, but it is not a universal requirement for every continuous process.
  • Material diversion needs a physical path: When the monitoring and control strategy identifies potentially non-conforming material, the system may need to divert that material away from acceptable product according to predefined criteria. That diversion path is a design decision, not just a software setting.
  • Process dynamics influence physical configuration: Residence Time Distribution (RTD) describes how long material spends moving through a process and is influenced by factors such as equipment design and configuration. Understanding RTD and process dynamics supports material tracking and helps determine appropriate sampling and diversion strategies, making equipment arrangement and connections important engineering considerations.
  • Utilities need to support the planned operating profile: Compressed air, nitrogen, process water, power, and other required utilities need to be evaluated against the intended run duration, simultaneous demand, operating range, and required system reliability rather than automatically being sized for round-the-clock operation.
  • Automation and control infrastructure take on a bigger role: With CM, the control system tracks the process in real time, so automation architecture, operator interfaces, control-panel locations, and data infrastructure become core parts of the facility design alongside the process room itself.

Steps to Plan a Facility Around ICH Q13

Here is a simple order of operations for teams starting a CM project:

  1. Define the process train early: Know which unit operations will run in a connected line and which, if any, will remain in batch mode before you sketch the room layout.
  2. Map monitoring and sensor locations. Decide where the process needs real-time monitoring, including PAT where appropriate, then design power and data access around those points.
  3. Plan the material diversion and collection path: Build a physical route for potentially non-conforming material that keeps it separate from acceptable products and supports the defined material-disposition strategy.
  4. Size utilities for the planned operating profile: Confirm that compressed air, nitrogen, process utilities, and power supply can handle the intended run duration, simultaneous loads, and required reliability.
  5. Design the automation infrastructure alongside the process room: Treat data infrastructure, control panels, operator interfaces, and cable routing as core parts of the layout, not an add-on.
  6. Build in a validation strategy that supports the state of control: CM can use traditional process validation or continuous process verification, depending on the process and justification. The facility, automation, and monitoring systems therefore need to support the data collection required for the selected validation approach throughout the manufacturing run.
  7. Train operators for a connected process: Running a CM line calls for a different skill set than managing discrete batch steps, so training plans should reflect that.

ICH Q13 also treats start-up, shutdown, pauses, restarts, and unplanned disturbances as important transient events. Their impact on material quality and process dynamics should therefore be understood when developing the operating and control strategy. 

Building Pharma Facilities Around Automation

Building Pharma Facilities Around Automation

Moving to continuous manufacturing usually means moving toward higher levels of integrated automation around the CM process, rather than simply automating individual pieces of equipment. This is where pharma manufacturing automation and facility design have to work together from day one. A control system that can manage real-time diversion, batch definition, and data capture only works if the physical layout supports it, with the right cabling paths, panel locations, and access for maintenance.

Companies offering pharma engineering solutions increasingly build this thinking into early-stage design rather than treating automation as a later add-on. Pharma Access brings process design, automation, utilities, facility engineering, and CQV considerations together during engineering development across its pharmaceutical projects, so the systems can be coordinated before construction starts.

Common Mistakes in ICH Q13-Aligned Facility Design

A few issues show up often when teams move to CM without planning the building around it:

  • Treating automation as a bolt-on: Retrofitting sensors, cabling, and control panels into a finished room can create avoidable rework and integration complexity compared with designing them into the facility from the start.
  • Underestimating utility demand: Longer CM runs can create sustained equipment and utility loads, and supporting systems designed only around intermittent batch operating profiles may not suit the intended CM run duration or operating range.
  • Skipping the diversion path in early layouts: Without a planned route for potentially non-conforming material, teams end up improvising later, which can complicate operation, qualification, and the material-diversion strategy.
  • Ignoring process dynamics and RTD: Changing equipment arrangement, connections, or hold-up volumes without understanding their effect on material movement can affect traceability, sampling, and diversion decisions.
  • Forgetting operator training needs: A connected line runs differently than a batch process, and operators need to understand the new failure points.
  • Designing the process room without the automation infrastructure in mind:Data infrastructure, operator interfaces, controls, and equipment connections have to develop alongside the process rather than being squeezed in afterward.

Why Work With Pharma Turnkey Consultants

CM projects bring process engineering, equipment integration, automation, utilities, facility design, and validation together at the same time which is a lot to coordinate without a single team managing the full picture. That is where pharma turnkey consultants add real value, since they carry a project from early engineering design through construction, procurement, and commissioning under one plan instead of handing it off between separate vendors at each stage.

Pharma Access works this way across its projects, offering engineering design services for pharma clients alongside construction, procurement, and commissioning, qualification, and validation (CQV) support. For a CM project, having one team track the process design, the automation plan, and the physical build together helps catch conflicts early, before they turn into rework.

Wrapping Up

ICH Q13 gives the industry a shared set of expectations for continuous manufacturing, but meeting those expectations comes down to how well the facility is built around the process. Map the process train early, plan for real-time monitoring and material diversion, understand process dynamics and RTD, size utilities around the intended operating profile, and treat automation and data infrastructure as part of the core layout. Get that sequence right, and the facility supports the process instead of working against it.

Frequently Asked Questions

What is ICH Q13? 

ICH Q13 is a guideline that sets scientific and regulatory expectations for continuous manufacturing of drug substances and drug products. It covers process development, control strategy,process dynamics, equipment design and system integration, process monitoring and control, process validation, and lifecycle management under one connected approach.

When did ICH Q13 become effective? 

The final guideline was adopted on November 16, 2022, and it became legally effective in the EU on July 10, 2023. The FDA issued its final Q13 guidance in March 2023. Different regions have their own timelines for adopting ICH guidelines into local regulation.

How is continuous manufacturing different from batch manufacturing? 

In batch manufacturing, product moves through manufacturing steps as defined batches. In continuous manufacturing, materials are continuously fed, transformed, and removed while the process operates. ICH Q13 also allows some unit operations to remain in batch mode while other directly connected operations run continuously.

Does ICH Q13 apply to biologics? 

Yes. ICH Q13 applies to continuous manufacturing of chemical entities and therapeutic proteins. Annex III specifically addresses continuous manufacturing of therapeutic protein drug substances, while the guideline notes that its principles may also apply to other biological and biotechnological entities.

What facility changes does continuous manufacturing usually require? 

Plants may need integrated equipment arrangements, defined material-transfer interfaces, suitable monitoring and sampling locations, material-diversion and collection points, automation and data infrastructure, utilities matched to the intended operating profile, and sufficient access for operation and maintenance. The exact facility changes depend on the process and CM configuration.

Does ICH Q13 require Process Analytical Technology (PAT)?

No. ICH Q13 states that PAT is well suited to continuous manufacturing and provides examples of its use for process monitoring and control, but it does not make PAT a universal requirement for every CM process. The monitoring strategy should be appropriate to the process and its control strategy. 

Does continuous manufacturing eliminate pharmaceutical batches?

No. ICH Q13 retains the concept of a batch for continuous manufacturing. Batch size can be defined by the quantity of output material, quantity of input material, run time at a defined mass flow rate, or another scientifically justified approach, and it can also be established as a range.

Posted on

Building Africa’s Pharma Manufacturing Base: What the AMA and the 60%-by-2040 Goal Mean for Facility Investment

Building Africa's Pharma Manufacturing Base: What the AMA and the 60%-by-2040 Goal

Africa’s pharma manufacturing base is at a turning point. For decades, the continent has relied on imported medicines and vaccines, a dependency that COVID-19 exposed in painful detail. Now two forces, a new continental regulator and a bold production target, are pushing governments and manufacturers toward a different future. This post looks at what those forces actually mean, and what it takes on the ground to turn the goal into working facilities.

Why Africa Still Imports Most of Its Medicines

The numbers explain the urgency. Africa imports more than 70% of the pharmaceuticals it consumes, while the WHO African Region imports 99% of its vaccines, with a significant share of pharmaceutical imports coming from Asian manufacturing markets. That reliance leaves the continent exposed every time a supply chain hiccup hits somewhere else in the world, and it can add logistics costs, duties, longer lead times, and supply-chain exposure. Local manufacturing can reduce some of these pressures, although its cost competitiveness ultimately depends on production scale, capacity utilisation, input costs, infrastructure, and operating efficiency.

This is not a new problem, but it took a pandemic to turn it into a policy priority.

What Is the African Medicines Agency (AMA)?

The African Medicines Agency was created to address one of the biggest roadblocks to local manufacturing: a fragmented regulatory landscape. Without stronger continental coordination, manufacturers seeking access across multiple African markets have had to navigate fragmented national and regional regulatory requirements, with differing procedures and timelines.

The AMA is a specialised health agency of the African Union designed to strengthen the capacity of participating member states and recognised Regional Economic Communities to regulate medical products, support regulatory harmonisation, and coordinate existing regulatory efforts rather than replace national medicines regulators. As of 22 May 2026, thirty-one African Union member states had ratified or acceded to the treaty establishing the agency and deposited their instruments, marking a continuing institutional shift toward stronger regional regulatory cooperation.

The 60%-by-2040 Goal, Explained

Here is the target at the centre of the sector’s local-manufacturing agenda. Africa CDC, through its Partnerships for African Vaccine Manufacturing (PAVM) initiative, originally set a goal for Africa to manufacture 60% of its vaccine needs locally by 2040; in February 2026, African leaders broadened the continental ambition by declaring a goal to meet at least 60% of Africa’s health-product needs through local manufacturing by 2040. The AMA and this wider production ambition are complementary: one supports stronger and more harmonised regulatory systems, while the other creates a long-term manufacturing and demand objective worth building capacity for. 

A few numbers put the scale of this ambition in perspective:

  • More than 70% of pharmaceuticals consumed in Africa are imported, while 99% of vaccines used in the WHO African Region are imported, showing how limited local production remains relative to demand today.
  • Many African pharmaceutical facilities operate at 30–60% capacity, below the 70%+ utilisation rates reported in more advanced pharmaceutical manufacturing markets.
  • Pharmaceutical production is also concentrated: just eight countries account for 85% of Africa’s approximately 690 pharmaceutical manufacturing facilities.

Closing that gap by 2040 means building real production capacity, not just signing agreements.

What Facility Investment Actually Requires

What Facility Investment Actually Requires

A regulatory framework and a target date do not build a factory. Getting from policy to working production lines takes capital, infrastructure, and technical expertise, and each of these carries its own set of hurdles.

Infrastructure Gaps

Unreliable electricity, weak transportation networks, and limited access to advanced testing equipment all slow down manufacturing readiness. A pharma facility depends on consistent power for HVAC, water systems, and cold storage, so power reliability and utility resilience are critical early considerations for an engineering team before the manufacturing systems themselves can operate reliably. 

GMP-Compliant Facility Design

GMP-Compliant Facility Design

Many local manufacturers face a shortage of facilities built to Good Manufacturing Practice (GMP) standards, including proper HVAC systems and layout design. Retrofitting an existing building can achieve GMP requirements, but brownfield projects may face constraints related to personnel and material flows, segregation, HVAC zoning, utilities, structural capacity, equipment access, and maintainability. A structured engineering and GMP gap assessment is therefore needed to determine whether upgrading an existing building or developing a purpose-built greenfield facility offers the lower technical and lifecycle risk.

Skilled Workforce

A shortage of trained personnel affects both construction and ongoing operations. Facilities need staff who understand validation, quality systems, and day-to-day GMP practice, not just people who can run equipment.

High Capital Costs

Building a GMP-compliant facility carries a real price tag, and the burden of financing a full qualification, validation, and compliance programme is not small, especially during periods of economic pressure. This is one reason regional demand-pooling mechanisms and long-term offtake agreements matter so much. They give investors a clearer path to a return before they commit capital.

What Investors Should Define Before Facility Design Begins

Before committing capital, manufacturers and investors also need to define the intended product portfolio, dosage forms, production capacity, target regulatory markets, site infrastructure, demand assumptions, future expansion requirements, and the CQV strategy. These decisions directly influence facility size, cleanroom classification, utility loads, process equipment, CAPEX, operating cost, and the choice between greenfield and brownfield development. Building these requirements into the project definition early reduces the risk of designing capacity that cannot operate competitively or support the intended market.

How Modern Engineering Tools Fit Into the Picture

As new facilities get planned across the continent, the design and construction process itself is changing. Simulation-based pharmaceutical engineering, including computational fluid dynamics (CFD), digital modelling, and AI-assisted analysis, is increasingly used to evaluate airflow, simulate HVAC performance, and identify layout issues before construction starts, rather than after.For a region trying to build capacity quickly and get it right the first time, catching design problems on a screen instead of on a half-built facility saves both time and money.

This matters more in Africa’s context than almost anywhere else. With capital tight and timelines tied to regional demand targets, a facility that requires major late-stage design corrections, rework, or repeat qualification can create delays and additional costs that investors need to plan for from the beginning.

Where Cleanroom Validation Fits Into the 2040 Target

Where Cleanroom Validation Fits Into the 2040 Target

None of this production capacity means anything if the facilities cannot pass inspection. A Cleanroom Validation Procedure, more precisely described in pharmaceutical GMP terminology as cleanroom qualification, uses ISO 14644 classification principles together with applicable GMP requirements to provide documented evidence that classified environments perform as intended. Depending on the facility and applicable requirements, qualification can include particle classification, HEPA-filter integrity testing, airflow volume and velocity, pressure differentials, airflow visualisation, microbial contamination, temperature, relative humidity, recovery, and other relevant tests. For African manufacturers targeting WHO prequalification or regulated regional and export markets, cleanroom qualification is an important part of GMP readiness where classified cleanrooms are required. It provides documented evidence of controlled-environment performance, but it does not by itself constitute product approval or WHO prequalification. 

Late or incomplete qualification can result in deviations, rework, retesting, and delays during facility start-up or inspection readiness. Building qualification requirements into the design and construction timeline from day one, rather than treating them as a final checkbox, gives a facility a stronger basis for achieving its planned qualification and start-up schedule. 

Why International Partnerships Matter

Africa does not need to build this manufacturing base alone, and international collaboration, technology transfer, skills development, and strategic partnerships are already part of the continent’s local-manufacturing agenda. Partnering with experienced pharmaceutical engineering consultants in India https://www.pharmaaccess.net/ can bring design and construction knowledge from a country that has already built a mature generics manufacturing ecosystem. That experience, applied appropriately to the regulatory, infrastructure, product, and operating requirements of individual African markets, can shorten the learning curve considerably.

Good Pharma Project Management Services matter just as much as the engineering itself. Coordinating design, procurement, construction, and validation as one connected process avoids the fragmented handoffs that lead to rework, delays, and budget overruns, all of which are harder to absorb in markets where capital is already tight.

At Pharma Access, we work on engineering design, construction, and CQV (commissioning, qualification, and validation) for pharma facilities across multiple countries, bringing more than 25 years of technical and operational experience to projects that need to integrate GMP, operability, and qualification requirements from the design stage onward. The manufacturer remains responsible for GMP operations, its pharmaceutical quality system, and applicable regulatory approvals, while the engineering and project team coordinates the agreed scope through design, construction, commissioning, qualification, and handover. If your organization is planning a facility to support Africa’s pharma manufacturing base, our team can help translate a production target into an engineered, commissioned, and qualification-ready facility. You can learn more about our approach on the Pharma Access about page.

Wrapping Up

The AMA and the 60%-by-2040 goal give the continent’s pharma sector a clear direction, but direction alone will not build the plants needed to get there. Reliable power, GMP-compliant design, trained staff, and rigorous qualification & validation all have to come together, project by project, facility by facility. 

The countries and companies that treat facility investment as a technical and engineering challenge, not just a policy commitment, will be the ones best positioned to contribute meaningfully toward Africa’s 2040 local-manufacturing ambition.

FAQs

What is the African Medicines Agency (AMA)? 

The AMA is a specialised health agency of the African Union established to strengthen regulatory capacity, support harmonisation of medicines regulation, and coordinate existing regulatory efforts across participating member states and regional bodies. It complements rather than replaces national medicines regulatory authorities.

What does the “60% by 2040” goal actually mean? 

The original PAVM target called for Africa to manufacture 60% of its vaccine needs locally by 2040. In February 2026, African leaders broadened the continental ambition to meet at least 60% of Africa’s health-product needs through local manufacturing by 2040.

Why do so many African pharma facilities struggle with GMP compliance? 

Common barriers include unreliable electricity, limited access to GMP-compliant facility infrastructure, a shortage of trained personnel, and the high upfront cost of building and qualifying a facility to international standards.

Why is cleanroom validation so important for new African facilities? 

Cleanroom qualification provides documented evidence that classified environments meet their defined cleanliness and performance requirements. It is an important part of GMP readiness for facilities that require controlled environments, although cleanroom qualification alone does not constitute regulatory approval or WHO prequalification.

How can international partners help Africa reach its manufacturing goals? 

Experienced engineering and project management partners can bring facility design, construction, commissioning, qualification, technology-transfer, and project-delivery expertise from established pharmaceutical manufacturing markets, helping African project teams reduce avoidable rework and build local capability as manufacturing capacity expands.